Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab +/- Carfilzomib vs Standard of Care in Relapsed/Refractory Multiple Myeloma
NCT07222761Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2026
- Primary completion
- May 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of linvoseltamab in multiple myeloma (MM), sponsored by Regeneron Pharmaceuticals. Started Jan 2026; status: recruiting.
02
Drugs
linvoseltamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07222761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222761.